Budesonide HFA pMDI

DRUG4 trials

Sponsors

AstraZeneca

Conditions

Asthma

Phase 3

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

CompletedNCT00419952

AstraZenecaAsthma

Start: 2007-02-28End: 2009-11-30Updated: 2012-10-30

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

CompletedNCT00419757

AstraZenecaAsthma

Start: 2007-01-31End: 2008-06-30Updated: 2012-08-27

A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects

CompletedNCT00449527

AstraZenecaAsthma

Start: 2007-03-31End: 2007-08-31Updated: 2011-01-24

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

CompletedNCT00449501

AstraZenecaAsthma

Start: 2007-03-31End: 2007-11-30Updated: 2011-01-24

Related Papers

Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial.

2012-04-2514 citations

The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma.

2012-03-013 citations

Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial.

2011-07-146 citations